Projected Price to Earnings: Opthea (OPT)

OPT (Opthea) - company brandmark

The success of Opthea Limited (OPT) is based on the outcomes of final-stage clinical trials and liquidity levels. The dynamics of the company's forward P/E ratio clearly demonstrate these dependencies, where 0.00 is the current level of the indicator. Fundamentals are supported by the development of innovative antibodies against macular degeneration and the stable legal status of the Australian biotech within a safe haven jurisdiction of developed nations.

OPT - Opthea Projected Price to Earnings Ratio over the range 07/04/2022 - 06/28/2025

Summary analytical data breakdowns for Opthea Corp (OPT)

- stock quotes and analyst forecast:
Stock Price Opthea|OPT - Average Forecast Price
- company stock exchange capitalization indicators:
Market Valuation Opthea Ltd|OPT - Total Enterprise Value
- issuer book value statistics:
Book Value per Share Opthea|OPT - Total Stockholders' Equity|Market Value to Book Value Ratio opthea.com|OPT - Company Total Asset Base
- debt level and financial liquidity data:
Debt to Equity Opthea Limited|OPT - Long-Term Liabilities to Capital|Short-Term Debt to Equity Opthea Limited|OPT - Company Aggregate Indebtedness|Debt to Book Value Opthea Ltd|OPT - Amount of Long-Term Liabilities|Company Short-Term Debts Opthea|Quick Ratio opthea.com
- earnings and market ratios statistics:
OPT - Company Net Income|Projected Future Earnings Opthea Limited|OPT - P/E Multiple|Projected Price to Earnings Opthea Ltd.|OPT - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Opthea Ltd|OPT - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Opthea|OPT - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months opthea.com|OPT - Net earnings per share growth this year|Earnings growth forecast for next year Opthea Limited
Fundamental company valuation:Opthea OPT
Signature product of Opthea Limited

For Opthea Limited, whose business model relies on complex climate logistics for innovative retinal drugs, this indicator serves as a gauge of market expectations for future efficiency. The ratio of market capitalization to projected earnings, reflected through the company's forward P/E, allows for an assessment of the asset's premium and determines the business's margin of safety amid inflationary pressures.

Key competitors

Forward P/E Multiple ALC|BLCO - Projected Price to Earnings Ratio|Glaukos Corp. - Projected Price to Earnings|Apellis Corp (APLS) - Projected Price to Earnings Ratio|Belite Bio, Inc. - Forward P/E Multiple|Projected Price to Earnings Ratio ocutx.com|Harrow (HROW) - Future Price to Earnings|VRDN - Market Cap to Projected Earnings|Future Price to Earnings LENZ Pharma|Projected Price to Earnings Ratio oculis.com OCS|Future Price to Earnings EyePoint Pharmaceuticals (EYPT)|KOD: Price to Expected Earnings Ratio|Aldeyra Therapeutics, Inc. - Projected Price to Earnings|Market Cap to Future Earnings Ratio KALA (KALA BIO Inc.)|Opus Bio - Forward P/E Multiple|Future Price to Earnings Multiple OKYO (OKYO Pharma Limited)|ADVM: Forward P/E Multiple|Projected Price to Earnings Ratio outlooktherapeutics.com (OTLK)|CLSD (Clearside Biomedical, Inc.) - Forward P/E Multiple|Forward P/E Multiple NovaBay|Projected Price to Earnings KPRX (Kiora Pharmaceuticals)|ALIM (alimerasciences.com) - Future Price to Earnings Multiple|Future Price to Earnings Eyenovia EYEN|guardionhealth.com - Future Price to Earnings|Ocuphire Pharma - Forward P/E Multiple